Form 8-K - Current report:
SEC Accession No. 0001104659-25-062722
Filing Date
2025-06-26
Accepted
2025-06-26 06:05:20
Documents
14
Period of Report
2025-06-10
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2519052d1_8k.htm   iXBRL 8-K 25349
2 EXHIBIT 99.1 tm2519052d1_ex99-1.htm EX-99.1 15553
6 GRAPHIC tm2519052d1_ex99-1img001.jpg GRAPHIC 4330
  Complete submission text file 0001104659-25-062722.txt   218674

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA tbph-20250610.xsd EX-101.SCH 3020
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE tbph-20250610_lab.xml EX-101.LAB 34239
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tbph-20250610_pre.xml EX-101.PRE 22362
16 EXTRACTED XBRL INSTANCE DOCUMENT tm2519052d1_8k_htm.xml XML 3704
Mailing Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104
Business Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104 650-808-6000
Theravance Biopharma, Inc. (Filer) CIK: 0001583107 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36033 | Film No.: 251074992
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)